Published in Nat Genet on July 15, 2012
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med (2014) 0.97
Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncol Rep (2013) 0.91
Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell (2013) 0.90
Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Oncogene (2014) 0.89
Mtss1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia (2015) 0.87
Epigenetic deregulation in pediatric acute lymphoblastic leukemia. Epigenetics (2014) 0.86
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL). Leukemia (2014) 0.86
TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell (2016) 0.84
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest (2016) 0.81
Molecular signatures of chronic myeloid leukemia stem cells. Biomark Res (2013) 0.79
Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib. Theranostics (2016) 0.79
Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. J Clin Invest (2014) 0.77
Targeted Protein Degradation by Small Molecules. Annu Rev Pharmacol Toxicol (2016) 0.77
Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors. Oncogene (2014) 0.76
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase. BMC Cancer (2016) 0.75
Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma. Dis Markers (2016) 0.75
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature (2003) 14.35
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature (2003) 12.06
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood (2002) 6.64
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10
Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature (1999) 5.77
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature (2009) 4.99
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest (2010) 4.70
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer (2005) 4.30
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell (2007) 4.21
Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature (1995) 4.14
Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol (2006) 4.13
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med (1999) 4.06
Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol (2006) 3.98
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
Cancer stem cells: lessons from leukemia. Trends Cell Biol (2005) 3.90
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer (2007) 3.63
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A (2006) 3.48
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell (2007) 3.40
Pax5: the guardian of B cell identity and function. Nat Immunol (2007) 3.15
Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med (2000) 3.15
Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell (2007) 3.12
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell (2008) 3.01
Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer (2005) 3.01
The BCR-ABL story: bench to bedside and back. Annu Rev Immunol (2004) 3.00
Dominant negative MYC blocks transformation by ABL oncogenes. Cell (1992) 2.64
Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity (1999) 2.35
Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat Immunol (2003) 2.04
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell (2010) 1.92
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet (2009) 1.86
IRF8 regulates myeloid and B lymphoid lineage diversification. Immunol Res (2009) 1.68
Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci U S A (1999) 1.63
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood (2007) 1.61
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood (2005) 1.56
Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene (2002) 1.54
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia (2008) 1.54
IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood (2008) 1.53
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood (2007) 1.40
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood (2008) 1.37
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood (2010) 1.33
The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci U S A (2005) 1.29
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood (2000) 1.29
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res (2005) 1.21
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood (2008) 1.17
Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest (2008) 1.16
The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem (1997) 1.10
Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res (2004) 1.08
Specific recognition of the blk promoter by the B-lymphoid transcription factor B-cell-specific activator protein. J Biol Chem (1994) 1.04
Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities. J Oncol (2011) 0.89
Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia (2006) 0.84
High-resolution cell division tracking demonstrates the FLt3-ligand-dependence of human marrow CD34+CD38- cell production in vitro. Br J Haematol (1997) 0.80
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Transcriptional regulatory elements in the human genome. Annu Rev Genomics Hum Genet (2006) 7.18
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell (2008) 6.84
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell (2005) 4.32
Identification of direct DAF-16 targets controlling longevity, metabolism and diapause by chromatin immunoprecipitation. Nat Genet (2005) 4.15
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. Nature (2002) 3.93
Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell (2002) 3.56
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A (2006) 3.48
ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics (2010) 3.47
An elaborate pathway required for Ras-mediated epigenetic silencing. Nature (2007) 3.47
Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 3.41
Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA (2004) 3.16
Arginine-serine-rich domains bound at splicing enhancers contact the branchpoint to promote prespliceosome assembly. Mol Cell (2004) 2.90
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell (2005) 2.85
Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev (2006) 2.79
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell (2011) 2.57
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One (2006) 2.42
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42
Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature (2005) 2.42
Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science (2011) 2.36
U2AF homology motifs: protein recognition in the RRM world. Genes Dev (2004) 2.34
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol (2003) 2.26
RS domains contact splicing signals and promote splicing by a common mechanism in yeast through humans. Genes Dev (2006) 2.25
Heterologous immunity between viruses. Immunol Rev (2010) 2.20
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A (2002) 2.19
Differential requirement of SAGA components for recruitment of TATA-box-binding protein to promoters in vivo. Mol Cell Biol (2002) 2.16
A pathway of sequential arginine-serine-rich domain-splicing signal interactions during mammalian spliceosome assembly. Mol Cell (2004) 2.11
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood (2010) 2.08
PTEN loss in the Myf5 lineage redistributes body fat and reveals subsets of white adipocytes that arise from Myf5 precursors. Cell Metab (2012) 2.07
In vivo target of a transcriptional activator revealed by fluorescence resonance energy transfer. Genes Dev (2004) 1.99
Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell (2012) 1.98
F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature (2009) 1.93
Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc Natl Acad Sci U S A (2006) 1.91
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet (2009) 1.86
A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell (2010) 1.85
Virus-specific CD8 T cells in peripheral tissues are more resistant to apoptosis than those in lymphoid organs. Immunity (2003) 1.85
Structural basis for polypyrimidine tract recognition by the essential pre-mRNA splicing factor U2AF65. Mol Cell (2006) 1.83
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood (2012) 1.81
Mapping cellular hierarchy by single-cell analysis of the cell surface repertoire. Cell Stem Cell (2013) 1.80
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res (2012) 1.73
RS domain-splicing signal interactions in splicing of U12-type and U2-type introns. Nat Struct Mol Biol (2007) 1.67
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood (2010) 1.66
Maternal Rnf12/RLIM is required for imprinted X-chromosome inactivation in mice. Nature (2010) 1.64
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest (2006) 1.64
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood (2007) 1.61
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood (2011) 1.61
Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Res (2009) 1.61
Systematic analysis of essential yeast TAFs in genome-wide transcription and preinitiation complex assembly. EMBO J (2003) 1.59
TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol (2006) 1.57
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med (2010) 1.55
Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood (2011) 1.53
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood (2009) 1.52
CD8 memory T cells: cross-reactivity and heterologous immunity. Semin Immunol (2004) 1.50
HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol (2005) 1.50
Initiation of zebrafish haematopoiesis by the TATA-box-binding protein-related factor Trf3. Nature (2007) 1.47
Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife (2013) 1.44
Characterization of enhancer function from genome-wide analyses. Annu Rev Genomics Hum Genet (2012) 1.41
Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci U S A (2010) 1.41
p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science (2006) 1.40
Engraftment and differentiation of embryonic stem cell-derived neural progenitor cells in the cochlear nerve trunk: growth of processes into the organ of Corti. J Neurobiol (2006) 1.40
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl) (2007) 1.40
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood (2013) 1.38
Hypertrophic pulmonary osteoarthropathy disappearance despite lung cancer relapse. South Med J (2008) 1.38
Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. J Immunol (2002) 1.35
Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol (2007) 1.34
TRF3, a TATA-box-binding protein-related factor, is vertebrate-specific and widely expressed. Proc Natl Acad Sci U S A (2003) 1.34
A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. Genes Dev (2008) 1.33
Crystal structure of UAP56, a DExD/H-box protein involved in pre-mRNA splicing and mRNA export. Structure (2004) 1.33
Targeted connexin26 ablation arrests postnatal development of the organ of Corti. Biochem Biophys Res Commun (2009) 1.32
Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol Cell (2009) 1.31
Alveolar epithelial type II cells activate alveolar macrophages and mitigate P. Aeruginosa infection. PLoS One (2009) 1.31
NFIA haploinsufficiency is associated with a CNS malformation syndrome and urinary tract defects. PLoS Genet (2007) 1.30
The U2AF35-related protein Urp contacts the 3' splice site to promote U12-type intron splicing and the second step of U2-type intron splicing. Genes Dev (2010) 1.26
HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells. Blood (2012) 1.26
A low-cost exon capture method suitable for large-scale screening of genetic deafness by the massively-parallel sequencing approach. Genet Test Mol Biomarkers (2012) 1.26
Distinct activities of the DExD/H-box splicing factor hUAP56 facilitate stepwise assembly of the spliceosome. Genes Dev (2008) 1.25
Selective recruitment of TAFs by yeast upstream activating sequences. Implications for eukaryotic promoter structure. Curr Biol (2002) 1.25
Inhibition of apoptosis by ATFx: a novel role for a member of the ATF/CREB family of mammalian bZIP transcription factors. Genes Dev (2002) 1.24
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood (2014) 1.23
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J (2006) 1.21
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology (2013) 1.16
Four additional mouse crosses improve the lipid QTL landscape and identify Lipg as a QTL gene. J Lipid Res (2009) 1.16
Mutations in OTOGL, encoding the inner ear protein otogelin-like, cause moderate sensorineural hearing loss. Am J Hum Genet (2012) 1.15
Homing and conversion of murine hematopoietic stem cells to lung. Blood Cells Mol Dis (2004) 1.15
PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo. Bioconjug Chem (2006) 1.15
A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2. RNA (2004) 1.14
A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife (2014) 1.12